FDA warns of rare skin reaction from Celgene's Revlimid

09/19/2008 | Wall Street Journal, The

Celgene's Revlimid, a treatment for blood cancer, may have caused 14 cases of Stevens-Johnson syndrome, a rare but serious skin reaction also known as toxic epidermal necrolysis, the FDA said on its Web site. The finding is based on the agency's postmarketing safety review of Revlimid, which was approved in December 2005.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT